Over the past two decades, integrative oncology — the evidence-informed use of mind-body practices, lifestyle interventions, and selected complementary therapies alongside conventional cancer treatment — has evolved from a fringe idea into a recognized clinical discipline. Leaders in the field demanded rigorous research, standardized methods, and randomized clinical trials. That work produced clinical practice guidelines jointly developed by the Society for Integrative Oncology (SIO) and the American Society of Clinical Oncology (ASCO), and integrative recommendations embedded in National Comprehensive Cancer Network (NCCN) guidance.
The field explicitly sought to apply the same evidentiary standards used for conventional oncology interventions. As a result, many integrative interventions now rest on randomized trials, meta-analyses, and systematic study rather than anecdote.
Randomized trials and meta-analyses report that specific integrative interventions meaningfully reduce a range of cancer-related symptoms. The published literature cited includes findings for reductions in cancer-related pain, fatigue, anxiety, depression, sleep disturbance, chemotherapy-related neuropathy, hot flashes, and treatment-related nausea. Beyond subjective symptom relief, some studies have measured biological changes such as altered immune markers, reduced inflammation, and changes in stress hormones. Those biological effects can affect patients’ ability to tolerate and complete lifesaving therapies.
Because better symptom control supports adherence to cancer treatment and can reduce complications, integrative approaches may influence clinical outcomes beyond quality of life alone.
Major oncology organizations now endorse integrative approaches in specific contexts. Examples include recommendations for acupuncture to address pain and chemotherapy-induced nausea, mindfulness-based interventions for anxiety, depression, and fatigue, and the incorporation of exercise and nutrition counseling into standard supportive care pathways.
When ASCO and NCCN endorse interventions as effective and safe, those endorsements typically carry decisive weight for clinical practice. The author argues that coverage policies should align with the same evidentiary standards used to develop these oncology guidelines.
Despite guideline endorsements, coverage for integrative oncology is inconsistent, fragmented, and inequitable across Medicare, Medicaid, and private insurers. Access often depends on geography, the patient’s insurer, or employer-negotiated benefits. Two patients with identical diagnoses can receive very different supportive care not because of differences in evidence but because of coverage variation.
From an economic perspective, many integrative services are lower-cost than invasive procedures or emergency care. Acupuncture sessions are less expensive than nerve blocks; group-based mindfulness programs cost far less than an emergency department visit for uncontrolled symptoms. Exercise and nutrition interventions can reduce downstream costs such as deconditioning, metabolic disease, hospitalizations, and may influence recurrence or progression. Yet insurers routinely cover high-cost drugs with modest benefit while leaving lower-cost, guideline-supported supportive therapies uncovered.
Coverage gaps are not purely accidental. Insurers often treat integrative therapies as optional rather than as evidence-based components of care. Some coverage policies reflect outdated perceptions of the evidence, and many benefits of integrative care appear as avoided complications or better treatment adherence — outcomes that are less visible on short-term claims analyses than the immediate cost of providing services.
The author frames this as a policy failure rather than a scientific one: the science underpinning many integrative approaches has advanced, but coverage decisions have not kept pace.
Research in integrative oncology has advanced beyond symptom relief into deeper biological questions. One area of controversy is biofield therapies — for example, reiki and healing touch — where practitioners touch or hold hands near patients. Historically dismissed for lacking plausible mechanisms and relying on subjective outcomes, biofield therapies are now being studied with objective endpoints and preclinical controls designed to minimize placebo effects.
The author’s group reported preclinical findings in which a standardized biofield protocol was associated with inhibition of pancreatic cancer cell growth and invasiveness in vitro and reduced liver metastasis in mouse models, with cellular changes in mitochondrial structure, cell cycle regulation, membrane voltage, and oncogenic pathways including FOXM1. Earlier studies showed altered immune cell infiltration and macrophage balance in lung cancer models. The clinical meaning of these preclinical signals remains uncertain, and the author emphasizes that more careful study is essential rather than silence or dismissal.
Some major health systems and programs have incorporated integrative and biofield therapies into supportive care. The Department of Veterans Affairs lists biofield therapies such as reiki and healing touch among its integrative health offerings. Across U.S. hospitals, these approaches are increasingly part of routine supportive care, often delivered by trained nurses working alongside conventional care teams. Cancer patients are already seeking these therapies, and many institutions have responded by offering them within clinical settings.
The author stresses that ignoring patients’ use of these therapies does not protect them; rather, it risks abandoning them. If therapies are ineffective, clinicians and patients should know so they can redirect resources; if they are effective, the boundaries of benefit must be defined and implemented responsibly.
The central policy recommendation is that coverage policies — for Medicare, Medicaid, and private insurers — should be updated to reflect SIO-ASCO and NCCN recommendations. Mandating coverage aligned with these guidelines would expand access, reduce disparities, and better reflect an evidence-based, patient-centered standard of cancer care.
The author calls this a matter of political will: the scientific groundwork for many integrative interventions has been laid, but insurers’ coverage policies have lagged. He argues that cancer patients and clinicians deserve supportive care guided by evidence, not by what insurers currently choose to cover.
The essay is authored by Lorenzo Cohen, Ph.D., a distinguished professor and integrative oncology researcher and a stage 3 melanoma survivor; he co-authored a book on lifestyle interventions titled Anticancer Living: Transform Your Life and Health with the Mix of Six.